HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ter Beek, W P Articles by Lamers, C B H W Search for Related Content PubMed PubMed Citation Articles by ter Beek, W P Articles by Lamers, C B H W

Gastrin releasing peptide receptor expression is decreased in patients with Crohn’s disease but not in ulcerative colitis

Department of Gastroenterology-Hepatology, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands

Correspondence to:
Dr I Biemond
Department of Gastroenterology-Hepatology, Leiden University Medical Centre, Building 1, C4-P; PO Box 9600, 2300 RC Leiden, the Netherlands; i.biemond{at}lumc.nl Background: Gastrin releasing peptide (GRP) and neuromedin B are bombesin (BN)-like peptides involved in regulating motility and inflammation in the gastrointestinal tract, which may be useful in treating inflammatory bowel disease (IBD). Three bombesin-like peptide receptors have been reported, but no studies have investigated their localisation in normal and inflamed human intestine.

Aim: To localise and characterise BN receptors in normal intestine and to see whether this is modified in IBD.

Methods: Full thickness intestinal tissue samples were collected from 13 patients with Crohn’s disease (CD), 11 with ulcerative colitis (UC), and 19 controls. BN receptor expression was characterised and quantified with storage phosphor autoradiography using BN, GRP, neuromedin B, and the synthetic analogue BN(6–14) as ligands.

Results: Only BN receptor type 2 (high affinity for GRP) was present in intestinal tissue. Minimal BN binding was detected in the mucosa. In normal colonic smooth muscle, mean BN binding was 336 fmol/g tissue in longitudinal muscle, including the myenteric plexus, and 71 fmol/g in circular muscle. In CD, colonic smooth muscle BN binding was significantly decreased (longitudinal muscle, 106; circular muscle, 19 fmol/g), in contrast to UC (377 and 62 fmol/g, respectively). In CD, a small (not significant) decrease was seen in ileal muscle compared with controls (111 v 169 and 18 v 32 fmol/g tissue for longitudinal and circular muscle, respectively).

Conclusions: Only the GRP receptor is expressed in human intestine; expression is highest in longitudinal muscle and myenteric plexus of the colon. Expression is decreased in inflamed and non-inflamed colon of CD, but not in UC.

Abbreviations: BN, bombesin; BN(6–14), [D-Phe⁶, ß-Ala¹¹, Phe¹³, Nle¹⁴]-bombesin(6–14); BRS-3, bombesin receptor subtype 3; CD, Crohn’s disease; GRP, gastrin releasing peptide; IBD, inflammatory bowel disease; NMB, neuromedin B; TNBS, 2,4,6-trinitrobenzenesulfonic acid; UC, ulcerative colitis

Keywords: bombesin receptor; inflammatory bowel disease; autoradiography

This article has been cited by other articles:

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]